secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMICUS THERAPEUTICS, INC. (—)
CIK:        0001178879
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001140361-25-046134
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amicus agrees to be acquired by BioMarin for $14.50 per share in cash
---------------------------------------------------------------------

- Merger consideration $14.50 per share; expected to close in Q2 2026.
- Termination fee of $175M payable by Amicus in certain termination scenarios.
- Transaction requires shareholder approval, HSR and foreign antitrust clearances.
- No-solicit restrictions apply; Amicus board may consider superior proposals under fiduciary duty.
- Bylaws amended to add exclusive forum provision (Item 5.03).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/0001140361-25-046134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/ef20061157_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-046134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer